Agenus Inc. (AGEN) Cash Flow Statement

The gap between net income and operating cash flow is not a timing artifact; it appears in every quarter where profits were reported. In 2026Q2, the company showed $0 net income against -$31.2M of operating cash outflow, suggesting the operating cash burn continues even when reported earnings neutralize. For investors, this pattern implies that reported profitability metrics overstate Agenus's economic performance and that cash generation — the true measure of a biotech's runway — remains structurally impaired.

A cumulative cash outflow of this magnitude relative to reported losses signals that investors relying on net income alone would materially underestimate the firm's capital consumption. The gap is partly explained by depreciation and stock-based compensation recognized as non-cash charges, but also by working capital swings that have consumed cash in multiple quarters. This divergence warrants monitoring of whether future reported profits can be sustained without continuing the cumulative cash drain.

The trajectory does not show a clear inflection toward self-sustaining cash generation; the least negative quarter (-$14.7M in 2025Q3) coincided with a large non-operating gain rather than operational improvement. Recent quarters (2026Q1 and 2026Q2) saw FCF margins of -106.6% and -90.4%, respectively, suggesting that any revenue growth achieved is still outpaced by operating outflows. Investors should monitor whether declining SG&A and rising revenue — as noted in the income statement analysis — translate into positive operating cash flow in coming quarters.

The absence of any buybacks or dividends is consistent with a pre-commercialization biotech deploying capital into pipeline assets rather than returning cash, but the scale of the acquisition outflow is notable given the company's sustained operating cash burn. The offsetting $63.9M inflow in 2026Q1 suggests the acquisition may have been asset-disposal-funded or structured, which warrants further investigation. For investors, the key question is whether the acquired asset generates meaningful cash or further research spend — neither outcome is visible from the cash flow statement alone.